Rapidly progressive dementias - aetiologies, diagnosis and management

被引:48
作者
Hermann, Peter [1 ,2 ]
Zerr, Inga [1 ,2 ,3 ]
机构
[1] Univ Med Ctr, Clin Dementia Ctr, Dept Neurol, Gottingen, Germany
[2] Univ Med Ctr, Natl Reference Ctr CJD Surveillance, Gottingen, Germany
[3] German Ctr Neurodegenerat Dis DZNE, Gottingen, Germany
关键词
CREUTZFELDT-JAKOB-DISEASE; FRONTOTEMPORAL LOBAR DEGENERATION; NMDA-RECEPTOR ENCEPHALITIS; DIFFUSION-WEIGHTED MRI; PRIMARY CNS LYMPHOMA; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; CLINICAL-FEATURES; SPORADIC CJD; CASE SERIES;
D O I
10.1038/s41582-022-00659-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The term 'rapidly progressive dementia' (RPD) describes a cognitive disorder with fast progression, leading to dementia within a relatively short time. This Review discusses the wide range of RPD aetiologies, as well as the diagnostic approach and treatment options. Rapidly progressive dementias (RPDs) are a group of heterogeneous disorders that include immune-mediated, infectious and metabolic encephalopathies, as well as prion diseases and atypically rapid presentations of more common neurodegenerative diseases. Some of these conditions are treatable, and some must be diagnosed promptly because of their potential infectivity. Prion disease is considered to be the prototypical RPD, but over the past two decades, epidemiological reports and the identification of various encephalitis-mediating antibodies have led to a growing recognition of other encephalopathies as potential causes of rapid cognitive decline. Knowledge of RPD aetiologies, syndromes and diagnostic work-up protocols will help clinicians to establish an early, accurate diagnosis, thereby reducing morbidity and mortality, especially in immune-mediated and other potentially reversible dementias. In this Review, we define the syndrome of RPD and shed light on its different aetiologies and on secondary factors that might contribute to rapid cognitive decline. We describe an extended diagnostic procedure in the context of important differential diagnoses, discuss the utility of biomarkers and summarize potential treatment options. In addition, we discuss treatment options such as high-dose steroid therapy in the context of therapy and diagnosis in clinically ambiguous cases.
引用
收藏
页码:363 / 376
页数:14
相关论文
共 150 条
  • [61] Neurologic Features in Severe SARS-CoV-2 Infection
    Helms, Julie
    Meziani, Ferhat
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (23) : 2268 - 2270
  • [62] Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease
    Hermann, Peter
    Appleby, Brian
    Brandel, Jean-Philippe
    Caughey, Byron
    Collins, Steven
    Geschwind, Michael D.
    Green, Alison
    Haik, Stephane
    Kovacs, Gabor G.
    Ladogana, Anna
    Llorens, Franc
    Mead, Simon
    Nishida, Noriyuki
    Pal, Suvankar
    Parchi, Piero
    Pocchiari, Maurizio
    Satoh, Katsuya
    Zanusso, Gianluigi
    Zerr, Inga
    [J]. LANCET NEUROLOGY, 2021, 20 (03) : 235 - 246
  • [63] Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance
    Hermann, Peter
    Laux, Mareike
    Glatzel, Markus
    Matschke, Jakob
    Knipper, Tobias
    Goebel, Stefan
    Treig, Johannes
    Schulz-Schaeffer, Walter
    Cramm, Maria
    Schmitz, Matthias
    Zerr, Inga
    [J]. NEUROLOGY, 2018, 91 (04) : E331 - E338
  • [64] Seizures in alcohol-dependent patients - Epidemiology, pathophysiology and management
    Hillbom, M
    Pieninkeroinen, I
    Leone, M
    [J]. CNS DRUGS, 2003, 17 (14) : 1013 - 1030
  • [65] Faciobrachial Dystonic Seizures Precede Lgi1 Antibody Limbic Encephalitis
    Irani, Sarosh R.
    Michell, Andrew W.
    Lang, Bethan
    Pettingill, Philippa
    Waters, Patrick
    Johnson, Michael R.
    Schott, Jonathan M.
    Armstrong, Richard J. E.
    Zagami, Alessandro S.
    Bleasel, Andrew
    Somerville, Ernest R.
    Smith, Shelagh M. J.
    Vincent, Angela
    [J]. ANNALS OF NEUROLOGY, 2011, 69 (05) : 892 - 900
  • [66] NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
    Jack, Clifford R., Jr.
    Bennett, David A.
    Blennow, Kaj
    Carrillo, Maria C.
    Dunn, Billy
    Haeberlein, Samantha Budd
    Holtzman, David M.
    Jagust, William
    Jessen, Frank
    Karlawish, Jason
    Liu, Enchi
    Luis Molinuevo, Jose
    Montine, Thomas
    Phelps, Creighton
    Rankin, Katherine P.
    Rowe, Christopher C.
    Scheltens, Philip
    Siemers, Eric
    Snyder, Heather M.
    Sperling, Reisa
    Elliott, Cerise
    Masliah, Eliezer
    Ryan, Laurie
    Silverberg, Nina
    [J]. ALZHEIMERS & DEMENTIA, 2018, 14 (04) : 535 - 562
  • [67] Immunoglobulins and virus-specific antibodies in patients with Creutzfeldt-Jakob disease
    Jacobi, C
    Arlt, S
    Reiber, H
    Westner, I
    Kretzschmar, HA
    Poser, S
    Zerr, I
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2005, 111 (03): : 185 - 190
  • [68] James SL, 2019, LANCET NEUROL, V18, P56, DOI [10.1016/S1474-4422(18)30415-0, 10.1016/S1474-4422(18)30499-X, 10.1016/S1474-4422(19)30034-1]
  • [69] The prevalence of oligoclonal bands in the CSF of patients with primary neurodegenerative dementia
    Janssen, JC
    Godbolt, AK
    Ioannidis, P
    Thompson, EJ
    Rossor, MN
    [J]. JOURNAL OF NEUROLOGY, 2004, 251 (02) : 184 - 188
  • [70] CNS Vasculitis
    John, Seby
    Hajj-Ali, Rula A.
    [J]. SEMINARS IN NEUROLOGY, 2014, 34 (04) : 405 - 412